We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Diagenic Presents Test Data for Parkinson Disease at European IPA Meeting
News

Diagenic Presents Test Data for Parkinson Disease at European IPA Meeting

Diagenic Presents Test Data for Parkinson Disease at European IPA Meeting
News

Diagenic Presents Test Data for Parkinson Disease at European IPA Meeting

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Diagenic Presents Test Data for Parkinson Disease at European IPA Meeting"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DiaGenic ASA has announced that it had presented a poster on discriminatory assays for Parkinson and Alzheimer’s diseases at the European Regional Meeting of the International Psychogeriatric Association in Lisbon.

The study employed a peripheral blood-based assay with a specific Alzheimer’s gene expression signature developed using DiaGenic’s patented method. 

Researchers found that 19 out of 20 Parkinson-diagnosed patients could be discriminated from Alzheimer’s sufferers. Furthermore, a specific gene expression signature for Parkinson was also identified.

The study is part of a larger follow-on study validating DiaGenic’s Alzheimer’s gene expression assay on an ABI microarray platform, the results of which will be presented at the ICAD in Madrid in July. 

"These findings showing that our blood-based gene expression assay approach can also be applied to Parkinson disease is extremely encouraging," said Anders Lonneborg, CEO, DiaGenic ASA.

"Alzheimer’s and Parkinson have different underlying pathologies, but overlapping clinical profiles as many PD patients will also develop dementia."

"Our goal is develop simple blood-based tests that will enable physicians to discriminate between patients at an early stage, since an increasing number of studies show that early therapeutic intervention can make a significant difference in improving quality of life."

Advertisement